CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Compare tax exposure between dividend ETFs and taxable funds in 2024 to identify the lower-tax option for your goals.
28,172 articlesInvestors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Can the steady, branch-backed lender OneMain outpace the AI-powered growth of Upstart? This guide breaks down the str...
Arbor Homes launches its Arrival Series in Louisville, debuting homes from $199,995 to tackle rising housing costs. T...
A large required minimum distribution can push high earners into higher Medicare surcharge brackets. Here's how it wo...
Trump pledges temporary gas-price reductions at 25 Philadelphia-area stations ahead of Independence Day as crude pric...
Nautilus' early 2026 results could signal demand for home fitness gear and pricing power. This analysis breaks down t...
Investors weigh Pfizer's CFO transition as the broader market climbs. This look at the stock market today, june revea...
The IMF says the U.S. economy remains robust, but mounting deficits and tariff policy threaten long-term balance. Thi...
A growing number of families face a tight budget as memory-care costs push toward $95,000 per year for private facili...
A major box-office milestone puts spotlight on how music biopics monetize beyond ticket sales. Learn practical, money...
A viral moment about who might evangelize Elon Musk shines a light on how faith and finance intersect. This article b...
A marquee collaboration turned cautionary tale. Explore how a failed merch deal unfolded, what it cost, and how to sh...